Adverse events induced by immune checkpoint inhibitors
AL Perdigoto, H Kluger, KC Herold - Current opinion in immunology, 2021 - Elsevier
AL Perdigoto, H Kluger, KC Herold
Current opinion in immunology, 2021•ElsevierHighlights•Adverse events are frequent with checkpoint inhibitors and occurs with all tumor
types.•A single mechanism has not emerged as explaining all of these adverse events.•Host
factors such as genotype and microbiome may affect risk of the adverse events.•Studies are
identifying ways to stop adverse events without impeding tumor response.Immune
checkpoint inhibitors have revolutionized the treatments of cancers but are also associated
with immune related adverse events that can interfere with their use. The types and severity …
types.•A single mechanism has not emerged as explaining all of these adverse events.•Host
factors such as genotype and microbiome may affect risk of the adverse events.•Studies are
identifying ways to stop adverse events without impeding tumor response.Immune
checkpoint inhibitors have revolutionized the treatments of cancers but are also associated
with immune related adverse events that can interfere with their use. The types and severity …
Highlights
- Adverse events are frequent with checkpoint inhibitors and occurs with all tumor types.
- A single mechanism has not emerged as explaining all of these adverse events.
- Host factors such as genotype and microbiome may affect risk of the adverse events.
- Studies are identifying ways to stop adverse events without impeding tumor response.
Immune checkpoint inhibitors have revolutionized the treatments of cancers but are also associated with immune related adverse events that can interfere with their use. The types and severity of adverse events vary with checkpoint inhibitors. A single mechanism of pathogenesis has not emerged: postulated mechanisms involve direct effects of the checkpoint inhibitor, emergence of autoantibodies or autoreactive T cells, and destruction by toxic effects of activated T cells. Several host factors such as genotypes, preexisting autoimmune disease, inflammatory responses and others may have predictive value. Ongoing investigations seek to identify ways of modulating the autoimmunity without affecting the anti-tumor response with agents that are specific for the autoimmune mechanisms.
Elsevier